Abstract: An inhaler for inhalation of an inhalable dry powder is provided. The inhaler has (a) an outer shell having a first shell part and a second shell part; (b) a capsule holder having a chamber for holding a capsule, a capsule breaker for breaking open a capsule held within the chamber and a trigger for causing the capsule breaker to break open a capsule; (c) a support for supporting the capsule holder; and (d) an outlet for passage of dry powder from the capsule into a user. The capsule holder is positioned in the first shell part which has an aperture through which the trigger protrudes. The aperture has a cut-out in the rim of the first shell part and through which the trigger may pass when the capsule holder is removed from the first shell part.

Abstract: Described herein is an inhaler for inhalation of an inhalable dry powder. The inhaler comprises (a) an outer shell comprising a first shell part and a second shell part; (b) a capsule holder comprising a chamber for holding a capsule, a capsule breaker for breaking open a capsule held within the chamber and a trigger for causing the capsule breaker to break open a capsule; (c) a support for supporting the capsule holder; and (d) an outlet for passage of dry powder from the capsule into a user. The capsule holder is positioned in the first shell part which comprises an aperture through which the trigger protrudes. The aperture comprises a cut-out in the rim of the first shell part and through which the trigger may pass when the capsule holder is removed from the first shell part.

Abstract: Novel Formulations Partially and fully acylated cyclodextrins have been found to be soluble in HFA propellants, and therefore can be used to formulate stable HFA pMDIs both as suspensions and solutions.

Abstract: The invention relates to a novel procedure for the production of a high yield of small crystalline particles of a narrow size distribution.

Abstract: The invention relates to coating inhalation devices and their components by cold plasma (pulsed or continuous wave) with fluorinated acrylates. The process gives inhalation devices with improved product performance by reducing drug deposition on the coated parts.

Abstract: The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.